Mantell Joanne E, Morar Neetha S, Myer Landon, Ramjee Gita
MSPH, HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, Columbia University, New York, NY, USA.
Am J Public Health. 2006 Jun;96(6):1073-7. doi: 10.2105/AJPH.2004.047514. Epub 2006 May 2.
We examined perceptions of the effectiveness and acceptability of a candidate microbicide among 94 South African female sex workers who had participated in a phase 3 microbicide trial for HIV prevention.
Sixteen focus groups were conducted in 2001, 12 to 15 months after participants were informed that the candidate microbicide had been determined to be ineffective in preventing HIV and other sexually transmitted infections (STIs).
Participants clearly indicated that they understood the experimental nature of the candidate microbicide, and they recognized that they had been informed after the trial that the product was ineffective. Nevertheless, most continued to believe that the candidate microbicide helped prevent HIV and other STIs, alleviated reproductive tract pain and STI symptoms, and helped to clean the vagina.
These findings underscore the importance of understanding women's perceptions of the efficacy of candidate microbicides and the rationale for these beliefs. These issues need to be addressed in counseling throughout microbicide trials for HIV prevention. These results also demonstrate how desperate many women at high risk of HIV infection may be for new HIV prevention technologies.
我们调查了94名参与预防艾滋病病毒的3期杀微生物剂试验的南非女性性工作者对一种候选杀微生物剂有效性和可接受性的看法。
2001年,在参与者得知候选杀微生物剂被判定在预防艾滋病病毒和其他性传播感染方面无效后的12至15个月,进行了16次焦点小组讨论。
参与者明确表示他们理解候选杀微生物剂的试验性质,并且他们认识到在试验后被告知该产品无效。然而,大多数人仍然认为候选杀微生物剂有助于预防艾滋病病毒和其他性传播感染,减轻生殖道疼痛和性传播感染症状,并有助于清洁阴道。
这些发现强调了了解女性对候选杀微生物剂疗效的看法以及这些信念背后理由的重要性。在整个预防艾滋病病毒的杀微生物剂试验咨询过程中需要解决这些问题。这些结果还表明,许多面临艾滋病病毒感染高风险的女性对新的艾滋病病毒预防技术可能是多么渴望。